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Abstract 
Review on Head and Neck paragangliomas, with 
data on clinics, and the genes involved. 
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Note 
The paraganglionic system comprises the adrenal 
medulla and the extra-adrenal paraganglia. The 
former gives rise to pheochromocytomas whereas 
the latter give rise to (extra-adrenal) 
paragangliomas. The adrenal medulla is the largest 
collection of paraganglia, and the most common 
site of paragangliomas (called pheochromocytomas 
in this location). The extra-adrenal paraganglia are 
collections of specialized neuroendocrine cells 
closely associated with large blood vessels, cranial 
nerves, autonomic nerves and ganglia (Lack, 2007). 
The paraganglia extend from the base of the skull, 
on either side of the midline, down to the pelvic 
floor. They vary in size, being either barely visible 
under the naked eye (e.g., carotid bodies) or only 
apparent under light microscopy (e.g., laryngeal 
paraganglia). Hence, extra-adrenal paragangliomas 
(PG) may be located anywhere from the upper neck 
to the pelvic floor (Lack, 2007).  
The sympathetic paraganglia are encountered along 
the axis of the trunk (pre- and para-vertebral 
sympathetic chains) and in the pelvic floor. The 
parasympathetic paraganglia are found almost 
exclusively in the head and neck along the branches 
of the glossopharyngeal and vagus nerves (Barnes 
et al., 2005). Most extra-adrenal paragangliomas are 
encountered above the clavicles. Paragangliomas of 
the head and neck (HNPG) are found primarily at 
the bifurcation of the common carotid artery, in the 
middle ear temporal bone, along the course of the 
vagus nerve, and, exceptionally, in the orbit, nasal 
cavity, paranasal sinuses, nasopharynx, larynx, 
trachea, and thyroid (Barnes et al., 2005). The 
carotid bodies comprise the largest compact 
collection of paraganglia in this anatomic 
distribution, and although uncommon, carotid body 
paragangliomas (CBP) are the most common 
paragangliomas of the head and neck region (Lack, 
2007; Barnes et al., 2005). Only head and neck 
paragangliomas will be discussed in this review. 
Clinics and pathology 
Embryonic origin 
The adrenal medulla and the extra-adrenal 
paraganglia are of neural crest origin (Lack, 2005; 
Barnes et al., 2005). 
Etiology 
Familial inheritance (see below) and chronic 
hypoxia are the only known risk factors in CBP 
(Barnes et al., 2005; Hensen and Bayley, 2011). 
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The role of chronic hypoxia in the development of 
head and neck paraganglioma other than CBP (e.g. 
laryngeal or jugulotympanic paraganglioma) is 
debated.  
Chronic hypoxia is known to induce paraganglia 
hyperplasia (Hensen and Bayley, 2011). Since the 
carotid body plays a central role in oxygen sensing, 
the latter may be involved in paraganglioma 
tumorigenesis. Succinate dehydrogenase (SDH) 
mutations in paraganglial tumors (see below) lead 
to succinate accumulation resulting in hypoxia-
inducible factor 1 (HIF-1) stabilization through 
inhibition of prolyl hydroxylase-mediated 
degradation (Hensen and Bayley, 2011, King et al., 
2006). This "pseudo-hypoxia" state leads to HIF-
induced transcription of genes such as vascular 
endothelial growth factor (VEGF) and other growth 
factors. 
Epidemiology 
Paragangliomas of the head and neck region (HN) 
are rare, comprising 0.6% of HN tumors and 0.03% 
of all neoplasms.  
The most frequent locations of head and neck 
paraganglioma are (by decreasing order) carotid 
body, jugulotympanic and vagal. Paragangliomas 
more often arise in female patients, usually in the 
4th and 5th decades of life (Kimura et al., 2004). 
Hereditary paragangliomas commonly develop at 
least 10 years earlier compared to sporadic tumors 
(Boedeker et al., 2013). 
Clinics 
Carotid body paraganglioma  
Carotid body paraganglioma occurs on average in 
the fifth decade of life with a roughly equal sex 
distribution. A female predilection has been noted 
by some, most notably in series of CBP occurring at 
high altitude (Lack, 2007). CBP usually presents as 
a slowly growing asymptomatic mass located deep 
to the sternocleidomastoid muscle just below the 
angle of the mandible. It may cause pain, 
hoarseness, dysphagia, headache, bruit or thrill 
(Barnes et al., 2005). The patient may present with 
Horner's syndrome due to involvement of the 
cervical sympathetic chain and rarely, with carotid 
sinus syndrome (bradycardia, syncopal episodes). 
Hypertension due to catecholamine secretion is 
exceptional. The lesion may be mistaken for an 
enlarged salivary gland or lymph node, a branchial 
cleft cyst or rarely, a carotid aneurysm. The tumor 
may be bilateral, especially in the familial setting. 
In the latter, about one third of the patients have 
synchronous or metachronous bilateral tumors; 
multicentric paragangliomas may occur outside the 
head and neck region. CBP has been described in 
Carney's triad (extra-adrenal paraganglioma, 
gastrointestinal stromal tumor (GIST), and 
pulmonary chondroma) (Carney, 2009). 
Jugulotympanic paraganglioma  
Jugulotympanic paraganglioma (JTP) may arise 
from the glomus jugulare (paraganglia located in 
the vicinity of the jugular bulb, jugular 
paraganglioma) or, less frequently, from the glomus 
tympanicum (paraganglia located near the middle 
ear surface of the promontory/medial promontory 
wall of the middle ear, tympanic paraganglioma) 
(Lack, 2007). However, in large jugulotympanic 
neoplasms, it may not be possible to precise the 
exact site of origin. JTP develops in adults in the 
5th to 6th decade of life (age range 13-85 years) 
(Lack, 2007). Solitary JTP arises predominantly in 
females whereas familial cases occur mostly in 
men. In one large series of sporadic JTP, the female 
to male ratio was 6 to 1 with a mean age of 55 years 
(Brown, 1985). 
Tympanic paraganglioma is usually confined to the 
middle ear cavity. It may cause tinnitus or aural 
pulsations, and conduction type hearing loss due to 
involvement of the ossicles. Large tympanic 
paraganglioma may fill the middle ear cavity. 
Patients may display ear fullness or pain, otorrhea, 
chronic otitis media, vertigo/dizziness, and rarely, 
facial palsy (Lack, 2007; Barnes et al., 2005). On 
examination, a red vascular or bluish mass may be 
seen behind a bulging tympanic membrane or 
protruding through it into the external ear canal. 
Biopsy of the mass often results in severe bleeding. 
Similarly, patients with jugular paraganglioma may 
suffer from conductive type hearing loss, tinnitus, 
ear pain, facial palsy, and hemorrhage (Lack, 2007; 
Barnes et al. 2005). The lesion may extend within 
the petrous bone and intracranially, occasionally 
simulating a middle cranial fossa or 
cerebellopontine angle tumor. The jugular foramen 
syndrome results in paresis of cranial nerves IX to 
XII due to compression. 
JTP (especially hereditary forms) may be bilateral 
and coexist with CBP, which may also be bilateral, 
or with pheochromocytoma. 
Vagal paraganglioma  
Vagal paraganglioma (VP) arises from paraganglia 
found within or adjacent to the vagus nerve in the 
vicinity of the ganglion nodosum. VP usually 
presents as a slowly growing asymptomatic mass at 
the angle of the mandible or as a bulge in the lateral 
oropharyngeal wall. Cranial nerve deficits are 
observed in one third to two thirds of patients at the 
time of diagnosis. Vagus nerve palsy causes 
ipsilateral vocal cord dysfunction, hoarseness, or 
dysphagia (Lack, 2007; Barnes et al., 2005). Large 
tumors may compress other cranial nerves (IX, XI, 
and XII) in the jugular foramen resulting in 
dysphagia, atrophy of the tongue, and shoulder 
weakness. Ipsilateral Horner's syndrome may occur 
following cervical sympathetic chain impairment. 
Functional VP with catecholamine-induced 
hypertension is uncommon. Handling of such lesion 
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during surgical removal may induce wide 
fluctuations in systemic blood pressure. 
Laryngeal paraganglioma  
Laryngeal paraganglioma (LP) is a rare tumor 
derived either from the superior or inferior 
paraganglia of the larynx. The vast majority of LP 
arises in the supraglottic space and presents as a 
submucosal mass in the region of the aryepiglottic 
fold/false vocal cord (Lack, 2007). Only 15% 
occurs in the subglottis and 3% in the glottis. The 
right side of the larynx is more often involved than 
the left (ratio 2.3:1). Median age at diagnosis is 44 
years (5-83 years). LP is three times more common 
in women than in men. The major symptom is 
hoarseness variably associated with dysphagia, 
dyspnea, stridor, dysphonia, sore throat, coughing, 
haemoptysis, foreign body sensation, and otalgia 
(Lack, 2007; Barnes et al., 2005). 
Rare  intrasellar and parasellar paragangliomas  
have been reported (Lack, 2007). 
Paragangliomas are usually solitary, particularly in 
adults, but two or more separate tumors may be 
present. Occasional examples of 
paragangliomatosis have been reported (Karasov et 
al., 1982). When multiple, the tumors may appear 
synchronously or asynchronously. In case of 
additional paragangliomas, it is usually a carotid 
body or less frequently, a jugulotympanic tumor. 
Imaging 
On imaging, paraganglioma appears as a 
homogeneous, hypervascular, well-defined soft 
tissue mass. A heterogeneous enhancement may be 
observed if hemorrhage or thrombosis has occurred. 
Large tumors may erode the surrounding bone (e.g. 
labyrinth, jugular foramen). On magnetic resonance 
imaging (MRI), the tumor appears as a well-defined 
hypointense mass with areas of signal void on T1-
weighted sequences. On T2-weighted images, the 
signal is usually hyperintense. MRI provides high 
resolution but is less sensitive compared to CT scan 
for identifying bone erosion or destruction (Lack, 
2007; Barnes et al., 2005). On angiography, there is 
direct involvement of the carotid bifurcation in 
CBP with a lyre-like widening of the common 
artery bifurcation in lateral views. Vagal 
paragangliomas are located well above the carotid 
bifurcation and typically displace both external and 
internal carotid arteries anteromedially (Lack, 
2007). 
Octreotide scintigraphy helps confirm the 
neuroendocrine nature of the neoplasm and detect 
occult paragangliomas. The role of functional 
imaging procedures in the diagnosis of HNPG has 
increased in the last 10 to 15 years (Hensen et al., 
2013). 123I-meta-iodobenzyl-guanidine (123I-MIBG) 
or 111In-pentetreotide scintigraphy is useful when in 
doubt of the diagnosis and in whole-body screening 
for functional paraganglial tumors, particularly in 
familial settings (Chen et al., 2010). The 18F-
fluorodeoxyglucose-PET (18F-FDG-PET) is also 
useful in screening for multiple tumors and in 
detecting metastases (Chen et al., 2010). 
Malignant paraganglioma  
The diagnosis of malignant paraganglioma usually 
depends upon the demonstration of metastases to 
sites such as regional lymph nodes, liver, lung, or 
bone (i.e. paraganglial cells in non-neuroendocrine 
tissue). Aggressive local growth, large tumor size, 
encirclement of carotid vessels, incorporation of 
nerves, or invasion near the base of the skull also 
suggests malignancy, although definitive evidence 
is provided by metastases (Lack, 2007). Most head 
and neck paragangliomas are benign tumors. 
Parasympathetic paragangliomas (head and neck 
region), in contrast to their sympathetic 
counterparts (trunk, pelvis), are more often familial 
and less likely to be malignant. Malignant 
paragangliomas, as their benign counterparts, 
mainly arise from the carotid body, in the middle 
ear (jugulotympanic tumors), along the course of 
the vagus nerve, and exceptionally in the orbit, 
nasal cavity, paranasal sinuses, nasopharynx, 
larynx, trachea, and thyroid (Barnes et al., 2005). 
Malignancy rates up to 10% in HNPG have been 
reported but those rates vary from study to study. 
According to one study, 2-13% of CBP are 
malignant (Barnes and Taylor, 1990). Between 6% 
and 19% of vagal tumors have been reported to be 
malignant. For other head and neck locations, 
malignancy concerns less than 10% of PG (for 
example, 2 to 4% for JTP) (Lee et al., 2002). The 
highest malignancy rate was reported for nasal and 
paranasal PG (24%), followed by vagal (10%), 
jugulotympanic (5.1%), carotid body (1.41%), and 
laryngeal PG (1.36%) (Rinaldo et al., 2004). 
Sporadic (non-familial) CBP are more likely to be 
malignant than those that are familial (12% versus 
2.5%). Malignant paraganglioma may develop in 
adults at any age (20-80 years old). The median age 
at first diagnosis in the US National Cancer Data 
Base was 44 years (Lee et al., 2002). In another 
series, the mean age was 35 years at diagnosis with 
53% of patients being older than 40 (Moskovic et 
al., 2010). The sex ratio was approximately 1:1 in 
the cohort reported by Lee et al. (2004). In the 
series reported by Moskovic et al. (2010), 69% of 
the patients were males. 
Multicentric paragangliomas must be distinguished 
from true metastases. Most metastases are present 
at diagnosis or less than 5 years after initial 
presentation. However, some may be apparent 10 to 
20 years after the diagnosis of the primary tumor. 
Pathology 
Macroscopic examination 
Carotid body paraganglioma usually measures 
between 2 and 6 cm in diameter. It appears firm, 
rubbery, well circumscribed and surrounded by a 
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thin fibrous capsule. On cut surface, the appearance 
is heterogeneous with yellow, tan, pink, red or 
brown areas. Fibrosis and hemorrhage may be 
observed. The tumor may encase large blood 
vessels such as the external carotid. Jugulotympanic 
paraganglioma often appears as an irregular reddish 
mass. In jugular paraganglioma, the petrous 
temporal bone and the middle ear space may be 
replaced by tumor tissue as far as the tympanic 
membrane (Lack, 2007; Barnes et al., 2005). Vagal 
paraganglioma is oval or round and abuts directly 
onto the skull base. It usually ranges from 2 to 6 cm 
in diameter and is firm, well circumscribed and 
surrounded by a thin fibrous capsule. In a few 
instances, it may be poorly defined and locally 
infiltrative. It presents with a variegated appearance 
on cut surface or may be uniformly homogeneous. 
A portion of one or more large nerves, usually the 
vagus, is often attached (Lack, 2007; Barnes et al., 
2005). 
On macroscopic examination, malignant 
paragangliomas do not significantly differ from 
benign paragangliomas (except for the occasional 
presence of lymph node metastases). Malignant 
paragangliomas typically present as firm, reddish 
lesions. A fibrous capsule may be seen, but in most 
instances, the tumor is locally infiltrative. On cut 
surface, a variegated appearance is noted with 
yellow-brown, tan-pink, and/or red (hemorrhagic) 
areas (Lack, 2007; Barnes et al., 2005). 
Microscopic examination  
Paraganglioma is a neuroendocrine neoplasm 
composed of chief and sustentacular cells arranged 
in a characteristic nesting ("Zellballen") pattern 
(Lack, 2007; Barnes et al., 2005). The chief cells, 
which are more numerous than the sustentacular 
cells, display a relatively uniform alveolar 
arrangement. The sustentacular cells are flattened 
cells located at the periphery of the Zellballen and 
are impossible to identify in routinely stained 
sections. A prominent capillary network is present 
between the clusters of neoplastic cells. CBP 
harbors a higher density of chief cells compared to 
normal carotid body paraganglia. Neoplastic chief 
cells usually have an abundant, finely granular, 
eosinophilic cytoplasm containing neurosecretory 
granules (filled with catecholamines). The 
sustentacular cells are devoid of such granules. Cell 
borders may be well-defined with polygonal or 
angular contours. Vacuolar cytoplasmic changes 
may be seen. Nuclei may be round to oval with 
pseudoinclusions. Nuclear pleomorphism, 
hyperchromasia, and occasional mitotic figures are 
not indicative of malignancy (Lack, 2007; Barnes et 
al., 2005). Paraganglioma is often well-demarcated, 
surrounded by a fibrous capsule. Areas of capsule 
deficiency should not be regarded as true capsular 
invasion. Some paragangliomas display areas of 
hemorrhage or fibrosis. In CBP, the tumor may 
involve the adventitia of the carotid. Remnants of 
the normal carotid body may be seen. 
Compared to other paragangliomas, JTP tend to 
more vascular and cell nests are less uniform and 
frequently smaller. Some JTP present with marked 
sclerosis (Lack, 2007; Barnes et al., 2005). 
Malignant paraganglioma  
As already mentioned, a tumor is considered 
malignant only if there is metastasis to regional 
lymph nodes or to more distant sites, such as the 
lungs or bones. There are no accepted 
histopathological or immunohistochemical criteria 
for the diagnosis of malignancy in PG. Local 
compression and erosion of surrounding structures 
are generally not accepted as a sign of malignancy. 
Nuclear pleomorphism, mitoses, necrosis, vascular 
or perineural invasion are not reliable prognostic 
factors in paragangliomas; the same is true for the 
Ki-67 proliferation index (Barnes et al., 2005). 
Immunohistochemistry  
The chief cells express synaptophysin, 
chromogranin A, and neuron-specific enolase. They 
do not express cytokeratin or S100 protein. 
Conversely, sustentacular cells express S100 
protein as well as GFAP (glial fibrillary acidic 
protein). Immunostaining for S100 protein shows 
elongated, stellate or dendritic sustentacular cells at 
the periphery of the Zellballen (Lack, 2007; Barnes 
et al., 2005). According to some, biologically 
aggressive paragangliomas might have a reduced 
number of sustentacular cells (and express fewer 
neuropeptides) compared to benign lesions (Barnes 
et al., 2005). 
n normal paraganglia, the chief cells express SDH 
subunit B.  
In case of an SDH mutation (whatever the SDH 
subunit involved), as seen in some hereditary 
paraganglial tumors (see below), the staining for 
SDHB in neoplastic chief cells will be weaker or 
abolished. The sustentacular cells will still display 
positive staining, serving as an internal control. The 
SDHB staining will be retained in other hereditary 
tumor syndromes (e.g. von Hippel-Lindau or 
Multiple Endocrine Neoplasia type 2 (MEN2) 
syndrome) (see below). Such an immunostaining 
may guide the geneticist to which gene is involved 
in the disease pathogenesis. 
Differential diagnosis 
Differential diagnosis includes carcinoid tumor, 
medullary thyroid carcinoma, anaplastic carcinoma, 
metastatic melanoma and renal cell carcinoma 
(Barnes et al., 2005).  
The differential diagnosis of JTP comprises middle 
ear adenoma/adenomatous neoplasm, meningioma, 
hemangiopericytoma, and metastatic renal cell 
carcinoma. Meningioma involving the jugular 
foramen can mimic the more common JTP. 
Schwannoma can also involve the jugular foramen 
(Barnes et al., 2005). 
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Figure 1: Paraganglioma. Chief cells arranged in the characteristic Zellballen pattern. The cell nests are separated by 
fibrovascular septa. Hematoxylin and eosin staining (original magnification x200). 
 
 
 
Figure 2: Paraganglioma. Immunostaining for synaptophysin. Strong expression of the neuronal marker by the chief cells 
(original magnification x200). 
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Treatment 
Paragangliomas are slowly growing tumors. 
Complete surgical resection is the treatment of 
choice when feasible (Lee et al., 2002; Moskovic et 
al., 2010). Tumors involving the base of the skull 
may require adjuvant radiation therapy. 
Chemotherapy is largely ineffective. Prolonged 
follow-up is necessary since the neoplasm may 
metastasize after a long interval. 
In CBP, surgery may require sacrifice of branches 
of the carotid artery. The recurrence rate is between 
0 and 10% and may reflect partial resection and 
subsequent tumor re-growth. JTP can be locally 
aggressive neoplasms that destroy bone and extend 
intracranially, and they may recur (or persist) 
locally. Regional and distant metastases are 
uncommon. Radiation therapy, and in some cases 
surgery, offers a high rate of cure for localized 
neoplasms. Options for treatment of VP include 
surgery, radiation therapy, and in selected cases, 
observation (Moskovic et al., 2010). In most cases, 
the vagus nerve (and sometimes other cranial 
nerves) has to be sacrificed. Radiation therapy may 
be used in case of bilateral tumor. Eight per cent of 
vagal paragangliomas recurs after surgery, often 
reflecting inadequate excision. 
Because malignant paragangliomas are rare, the 
survival rate is only available from small case 
series.  
In one study, the 5-year overall survival was 59.5% 
(Lee et al., 2002). In case of metastases confined to 
regional lymph nodes, the 5-year survival rate was 
76.8% but decreased to 11.8% for patients with 
distant metastases (Lee et al., 2002). Adjuvant 
radiation therapy seems the most appropriate 
treatment in case of metastatic regional lymph 
nodes (Lee et al., 2002; Moskovic et al., 2010). 
Bone metastases occur frequently in JTP whereas 
CBP present with both bone and lung metastases 
(Moskovic et al., 2010). 
Genetics 
The classic "rule of 10" for paraganglial tumors (i.e. 
10% are malignant, 10% are hereditary and 10% are 
extra-adrenal) has become inaccurate (Fishbein et 
al., 2013). The identification of novel causative or 
susceptibility genes in pheochromocytomas and 
paragangliomas led to an increase in the rate of 
familial forms. About one third of all patients with 
(even apparently sporadic) HNPG are carriers of 
germline mutations. The rate varies between 24% 
and 32% (Fishbein et al., 2013) with one study 
reporting a rate as high as 41% (Burnichon et al., 
2009). But the true incidence of familial 
paragangliomas may be even higher (i.e. 50%). The 
mode of inheritance is autosomal dominant with, 
for some syndromes, genomic imprinting (see 
below) (Boedeker et al., 2013). As a result, no 
tumor occurs when the gene is inherited from the 
mother. Paragangliomas may appear in children 
after paternal transmission even if the father is 
unaffected. Because of the skipping of generations 
after maternal transmission, familial forms of the 
disease are most likely underestimated (Boedeker et 
al., 2013).  
Hereditary paragangliomas of the head and neck 
(HNPG) have been described in association with 
mutations of at least 10 different genes (Boedeker 
et al., 2013; Dahia, 2014).  
Mutations of the genes succinate dehydrogenase 
subunit D (SDHD), succinate dehydrogenase 
complex assembly factor 2 (SDHAF2, formerly 
known as SDH5), SDHC, and SDHB are the cause 
of paraganglioma syndromes (PGL) 1, 2, 3, and 4, 
respectively.  
These genes (as well as the SDHA gene, see below) 
encode subunits or cofactors of succinate 
dehydrogenase, which functions as the 
mitochondrial complex II (Baysal et al., 2000). The 
latter plays a key role in the mitochondrial 
respiratory chain as well as the tricarboxylic acid 
cycle (Boedeker et al., 2013; Dahia, 2014). 
Complete and selective loss of SDH enzymatic 
activity is observed in all SDHx-mutant PG 
regardless of the SDH gene involved. PGL1, 3, and 
4 account for 90% of hereditary HNPG. 
Succinate dehydrogenase subunit A (SDHA), von 
Hippel-Lindau (VHL), and transmembrane protein 
127 (TMEM127) gene mutations have also been 
associated with HNPG development (Boedeker et 
al., 2013; Dahia, 2014).  
HNPG in patients with rearranged during 
transfection (RET), neurofibromatosis type 1 
(NF1), and MYC-associated factor X (MAX) gene 
mutations have been described in rare instances 
(Boedeker et al., 2013; Dahia, 2014). 
Genes involved and 
proteins 
SDHD 
Location 
11q23.1 
Note 
Patients with SDHD gene mutations develop HNPG 
in 91% to 98% of cases (Boedeker et al., 2013). 
Multiple, synchronous or metachronous, HNPG are 
a key feature of this syndrome as they develop in 
most patients (60% to 79%).  
Pheochromocytomas and extra-adrenal PG are also 
observed in 16% to 21% of these patients. The 
prevalence of malignant paragangliomas reported in 
PGL1 individuals with manifest disease varied 
widely, ranging from 0% to 23%.  
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The pooled incidence for malignant PG was 8% in 
SDHD mutation carriers (van Hulsteijn et al., 
2012). Tumor penetrance is high: 50% by age 31 
rising to 86% by age 50 (Neumann et al., 2004). In 
another study (Hensen et al., 2010), age-related 
penetrance in patients with PGLA was 54% by age 
40 and 87% by age 70. The average range of age at 
diagnosis of SDHD-mutant tumors was 25 to 38 
years (Boedeker et al., 2013). There is also a high 
prevalence of occult paragangliomas in 
asymptomatic mutation carriers (Heesterman et al., 
2013).  
PGL1 families exhibit a peculiar inheritance pattern 
with a distinct "parent-of-origin dependent effect." 
(van der Mey et al., 1989). Although SDHD 
mutations (SDHD gene on chromosome 11q23.1) 
can be inherited both via the maternal and paternal 
lines, paraganglial tumors almost never develop 
after maternal transmission of the mutation 
(Boedeker et al., 2013). As maternally derived 
SDHD mutation carriers will still pass the mutation 
to their offspring in 50% of cases, PGL1 can seem 
to skip generations, which may in part explain the 
occurrence of SDHD germline mutations in 
apparently nonfamilial cases. This virtually 
exclusive paternal inheritance of disease is 
consistent with maternal imprinting of the disease 
gene (van der Mey et al., 1989). The fact that this 
inheritance pattern is also found in PGL2 families 
(linked to the SDHAF2 gene, located on 11q13), 
but not in PGL3 or PGL4 families, suggests that 
other genes on chromosome 11 are involved. In 
SDHD-linked paraganglial tumors, the whole 
maternal copy of chromosome 11 has been found 
selectively lost (Hensen et al., 2004). Thus, a 
second paternally imprinted tumor suppressor gene 
located elsewhere on chromosome 11 may play a 
decisive role in tumorigenesis, at least in PGL1 and 
PGL2. In the very few instances of maternal 
transmission of the disease in PGL1 families, not 
only was the SDHD or SDHAF2 gene affected but 
also was the 11p15 region (Pigny et al., 2008; Yeap 
et al., 2011). This putative tumor suppressor gene 
has yet to be identified. 
SDHAF2 
Location 
11q12.2 
Note 
A mutation of SDHAF2 gene on chromosome 
11q13 has been identified as the underlying cause 
of PGL2. PGL2 is also strongly associated with the 
occurrence of multiple HNPG (70% to 91%), but so 
far, no extra-adrenal PG, pheochromocytoma, or 
malignant PG have been described in SDHAF2 
mutation carriers (Boedeker et al., 2013). As in 
PGL1, transmission of PGL2 occurs exclusively via 
the paternal line. Tumor penetrance is very high 
(88% to 100%), and the average age at diagnosis is 
33-34 years old (Boedeker et al., 2013). 
SDHC 
Location 
1q23.3 
Note 
SDHC mutations have been detected less frequently 
than SDHD and SDHB mutations (Neumann et al., 
2009). In sharp contrast to patients with PGL1 and 
PGL4, SDHC mutation carriers mostly present with 
benign, single HNPG. Multiple HNPG are found in 
19% to 31% of patients, and pheochromocytomas, 
extra-adrenal PG, and malignant PG are seldom 
reported in PGL3 (Boedeker et al., 2013). The 
transmission is autosomal dominant. The 
prevalence for SDHC mutations in two large series 
of patients with HNPG was 3.6% and 4.3%, 
respectively (Burnichon et al., 2009; Neumann et 
al., 2009). Family history is positive in a minority 
of patients (12% to 25%), suggesting a low tumor 
penetrance (Neumann et al., 2009). The average age 
at diagnosis is higher than that observed in the other 
PGL (range: 38-46 years) (Burnichon et al., 2009). 
SDHB 
Location 
1p36.13 
Note 
PGL4 is defined by SDHB mutations (SDHB gene 
on chromosome 1p36). In contrast to SDHD 
mutation carriers, patients with SDHB mutations 
frequently develop extra-adrenal PG (52% to 84% 
cases) and pheochromocytomas (18% to 28% 
cases), and less frequently HNPG (27% to 31% 
cases), whereas multifocal HNPG rarely develop 
(Boedeker et al., 2013). The average age at 
diagnosis is 30 to 37 years old. The most striking 
clinical feature of PGL4 is the high percentage of 
malignant pheochromocytomas and HNPG, ranging 
from 20.6% to 41% (Neumann et al., 2009; Pasini 
and Stratakis, 2009). The pooled risk in prevalence 
studies, depending on the presence of manifest 
disease, ranged from 13% to 23% in PGL4. The 
incidence of malignant HNPG and 
pheochromocytomas is higher in SDHB than in 
SDHD mutation carriers but may be lower in PGL4 
than previously appreciated (van Hulsteijn et al., 
2012).  
In one study, identification of SDHB mutation was 
the only risk factor for mortality. The 5-year 
survival probability was 36% for patients with 
SDHB mutation versus 67% for patients without 
SDHB mutation with a median survival time of 42 
months for PGL4 patients versus 244 months for 
SDHB-wild type patients (Amar et al., 2007). 
SDHB mutations follow an autosomal dominant 
trait of inheritance. Tumor penetrance is somewhat 
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lower than that seen in SDHD mutation carriers. 
The age-related tumor penetrance in PGL4 was in 
one study 29% at age 30 rising to 45% at age 40 
(Benn et al., 2006).  
Patients with PGL develop HNPG and 
pheochromocytomas at a significantly younger age 
than patients with sporadic paraganglial tumors 
(Boedeker et al., 2013).  
The age at first manifestation of a paraganglial 
tumor was 36.2 years in the PGL group compared 
to 50 years in the group with sporadic tumors (p < 
0.0001) (Myssiorek et al., 2008).  
Multiple paraganglial tumors were also 
significantly more frequent in SDHx mutation 
carriers.  
Finally, patients with PGL also had a significantly 
higher risk for the development of malignant 
paraganglial tumors.  
PGL1, 3, and 4 are not only associated with 
paraganglial tumors but also with hereditary renal 
cell carcinoma (Ricketts et al., 2012; Paik et al., 
2014). PGL4 patients have an increased risk of 
developing papillary thyroid carcinoma, 
neuroblastoma, and breast cancer (Fishbein and 
Nathanson, 2012). Pituitary adenomas have been 
reported in PGL1 syndrome (Xekouki et al., 2012). 
VHL 
Location 
3p25.3 
Note 
Von Hippel-Lindau syndrome (VHL) is an 
autosomal dominant tumor syndrome caused by 
mutations of the VHL gene on chromosome 3p26-
25. VHL patients present with hemangioblastomas 
of the central nervous system, retinal angiomas, 
renal cell cysts and renal cell carcinomas, 
pancreatic cysts, as well as pheochromocytomas 
(Boedeker et al., 2013). In one study, 0.53% of 
patients with VHL syndrome were found to have 
HNPG (Boedeker et al., 2009). An association 
between HNPG and VHL syndrome has also been 
reported by Gaal et al. (2009). 
TMEM127 
Location 
2q11.2 
Note 
TMEM127 (Transmembrane protein 127) gene is 
located on chromosome 2q11. TMEM127 mutation 
has previously been associated with hereditary 
pheochromocytoma (Qin et al., 2010). In one study, 
two out of 48 patients (4.2%) with multiple 
paragangliomas and no mutation in the SDHB, 
SDHC, SDHD, RET and VHL genes were found to 
harbor a TMEM127 mutation (Neumann et al., 
2011). Others reported a TMEM127 mutation in 6 
out of 642 (0.9%) paraganglioma patients, none of 
whom had a HNPG (Abermil et al., 2012). 
SDHA 
Location 
5p15.33 
Note 
The SDHA gene (Succinate dehydrogenase subunit 
A), located on chromosome 5p15, encodes the 
major catalytic subunit of the SDH complex.  
In Korpershoek et al.'s study, seven of 316 patients 
(2.2%) with paragangliomas harbored an SDHA 
mutation.  
Two of those 7 mutation carriers presented with 
HNPG (Korpershoek et al., 2011) 
MAX 
Location 
14q23.3 
Note 
Recently, germline mutations in the MAX gene 
(MYC-associated factor X, chromosome 14q23) 
were identified in 1.12% of patients (out of 1700 
individuals) with pheochromocytomas and 
paragangliomas with no other known mutation 
(Burnichon et al., 2012). 
RET 
Location 
10q11.21 
Note 
Multiple endocrine neoplasia type 2 (MEN2) is an 
autosomal dominant syndrome associated with RET 
mutations (chromosome 10q11).  
So far, HNPG have only been described in 3 
patients with MEN2, and as a rule do not develop 
without other MEN2-associated manifestations 
(Boedeker et al., 2013). 
NF1 
Location 
17q11.2 
Note 
Neurofibromatosis type 1 is an autosomal dominant 
tumor syndrome caused by mutations of the NF1 
(neurofibromin 1) gene on chromosome 17q11. 
NF1 patients present with multiple neurofibromas, 
café-au-lait spots, axillary freckling, and Lisch 
nodules of the iris.  
One to five percent of NF1 mutation carriers 
develops pheochromocytomas (Walther et al., 
1999).  
An HNPG in a NF1 patient has only been described 
once (Boedeker et al., 2009).  
In a cohort of 809 patients with SDHx-wild type 
HNPG, no NF1 mutation was identified (DeAngelis 
et al., 1987). 
Head and Neck: Paraganglioma: an overview Rousseau A, Badoual C 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(5) 285 
 
To be noted 
Note 
The fact that some clearly familial HNPG do not 
seem associated with any of the known genes 
makes it very likely that other, yet to be discovered, 
genes are involved in the development of 
paraganglial tumors. Candidate genes are kinesin 
family member 1B (KIF1B) and prolyl hydroxylase 
domain 2 (PHD2) (Boedeker et al., 2013).  
Genetic testing  
Approximately one third of all patients with 
apparently sporadic HNPG suffer from mutations in 
one of the genes SDHD, SDHB, or SDHC 
(Boedeker et al. 2013). Recommendations on 
genetic screening are to test all patients presenting 
with paraganglioma before age 50, as well as those 
with malignant, multiple, or familial tumors (Pacak 
et al., 2007). Neumann et al. (2009) screened 598 
patients with apparently sporadic HNPG for 
mutations of those 3 genes. Mutations were found 
in 183 patients (30.6%) with 94 SDHD, 63 SDHB, 
and 26 SDHC gene mutations and no patient 
presenting with more than one mutation (Neumann 
et al., 2009). The authors defined six first step 
predictors: positive family history, previous 
pheochromocytoma, multiple HNPG, manifestation 
of first tumor before age 40, and male sex, as well 
as malignant HNPG (Neumann et al., 2009). A 
step-by-step approach could be used even though 
next-generation sequencing will reduce costs and 
probably allow for up-front screening for all the 
genes known to be involved in PG (McInerney-Leo 
et al., 2014). In the mean time, clinical parameters 
will help to decide which gene(s) should be tested 
first. Some authors recommend that all patients 
diagnosed with PG undergo genetic testing 
(Fishbein et al., 2013). In the study by Fishbein et 
al. (2013), the patients with mutation in the VHL, 
NF1, or RET gene did not have a known family 
history before presentation in 30˜70 % of cases. It is 
important to refer the patients to the medical 
genetics department for counseling and deciding 
which gene(s) to test first. In case of positive family 
history for paraganglial tumors, the mutation 
detection rate was 90% (Fishbein et al., 2013).  
All mutation carriers should undergo a clinical and 
radiologic screening after the genetic diagnosis has 
been established. The only exception may be 
children of female SDHD and SDHAF2 mutation 
carriers. In addition to a thorough physical 
examination, the following procedures should be 
considered: MRI with contrast medium of the head 
and neck, the thorax, and the abdomen; 
catecholamines or metanephrines in plasma or 24- 
hour urine, and functional imaging in some cases 
(Boedeker et al., 2013). The percentage of patients 
with SDHB and SDHD who develop a tumor 
during the first 2 decades of life is rather high. In 
the study by Burnichon et al. (2009), 21 of 242 
SDHB and SDHD mutation carriers (8.7%) 
developed a tumor by age 18. The authors therefore 
suggested beginning examinations in patients with 
SDHB and SDHD at age 6. Myssiorek et al. (2008) 
recommend to commence screening at age 10. 
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